Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin.

Antimicrobial Agents and Chemotherapy
H C Neu, G J Garvey

Abstract

The in vitro activity and human pharmacology of ticarcillin, a semisynthetic penicillin more active than carbenicillin against Pseudomonas, were compared. There has been no increase in resistance to ticarcillin of Pseudomonas strains over the past 5 years, but resistance of indole-positive Proteus and Serratia strains has been documented. After intramuscular (i.m.) injection of 1 g of ticarcillin, mean peak levels occurred at 1 h (26.9 mug/ml) with a decline over 6 h (6.8 mug/ml). Serum half-life was 84 min. Dilution of ticarcillin lidocaine reduced pain on i.m. injection but did not alter serum levels. Blood levels after 1 g i.m. are adequate to treat infections produced by Escherichia coli, Proteus mirabilis, and some Enterobacter, but not Pseudomonas. After rapid intravenous infusion of 3 and 5 g, mean peak serum levels of ticarcillin were slightly lower for 1 h than those achieved with carbenicillin. Probenecid administered before infusion produced increases in blood levels, half-lives, and volume of distribution. The biological half-life of ticarcillin was 72 min compared to 66 min with carbenicillin. There was a larger volume of distribution for ticarcillin than carbenicillin (15 liters versus 14 liters). The ticarcillin ...Continue Reading

References

Apr 1, 1975·Clinical Pharmacology and Therapeutics·R D LibkeW M Kirby
Jul 1, 1973·Antimicrobial Agents and Chemotherapy·V RodriguezG P Bodey
Oct 3, 1974·The New England Journal of Medicine·S M Wolff, J V Bennett
Feb 1, 1970·Applied Microbiology·J Burnett, R Sutherland

❮ Previous
Next ❯

Citations

Jan 1, 1989·Veterinary Research Communications·M S Bal, K S Brar
Feb 1, 1983·Theriogenology·W R Threlfall, T J Keefe
Oct 1, 1976·Antimicrobial Agents and Chemotherapy·V L Sutter, S M Finegold
Jun 1, 1978·Antimicrobial Agents and Chemotherapy·K P Fu, H C Neu
Dec 1, 1979·Antimicrobial Agents and Chemotherapy·E L FranckeH C Neu
Apr 1, 1980·Antimicrobial Agents and Chemotherapy·B R MeyersE Srulevitch
Jun 1, 1983·Antimicrobial Agents and Chemotherapy·S BennettJ Dent
Sep 1, 1986·Antimicrobial Agents and Chemotherapy·B J GuglielmoJ G Gambertoglio
Dec 1, 1986·Antimicrobial Agents and Chemotherapy·G L JungbluthW J Jusko
Apr 1, 1976·Antimicrobial Agents and Chemotherapy·M F Parry, H C Neu
Feb 1, 1977·The British Journal of Ophthalmology·A AhmadS Ohno
Feb 24, 2007·Journal of Zoo and Wildlife Medicine : Official Publication of the American Association of Zoo Veterinarians·Charles A ManireHoward L Rhinehart
Dec 1, 1980·Journal of Pharmacological Methods·E CelozziA K Miller
Dec 2, 2006·International Journal of Antimicrobial Agents·G N Rolinson, A M Geddes
Feb 18, 1988·The New England Journal of Medicine·G R Donowitz, G L Mandell
Jan 1, 1977·The Journal of International Medical Research·A Dalhoff, D Höffler
Nov 1, 1979·The American Journal of Medicine·S J PancoastH C Neu
Apr 1, 1979·International Journal of Dermatology·C Liu
Apr 1, 1985·Infection Control : IC·S M Norris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.